Ligand Pharmaceuticals

Ligand Pharmaceuticals reports that its royalty-aggregator model, introduced in 2022, is scaling and producing higher-margin, more predictable revenues; Q2 revenue rose 34% to $64 million and adjusted earnings per share increased 48% to $2.37. The acquisition of XOMA doubled the partnered portfolio to more than 220 programs and is expected to boost 2025 EPS by at least $1.50. Management raised its 2024 adjusted EPS guidance to $9.00–$9.50, sees several near- to mid-term approval catalysts (including FILSPARI, Palvella) and plans annual investments of $150–$250 million. At the same time the company warned of typical biotech risks such as clinical setbacks, reimbursement pressure and future patent expirations. » Więcej na de.investing.com

Ligand Pharmaceuticals achieves high profitability through a pure licensing-and-royalties model that reduces the development risks typical of biotech. Strategic moves — including the multibillion-dollar acquisition of XOMA — and key product approvals are driving forecasted license revenues to grow by more than 23% annually over the next five years. The stock has rallied above $320 and is regarded as a fundamentally solid/quality investment. » Więcej na finanzen.net

Ligand reported a 56% increase in license revenues for Q1 2026 to $43.0m, while adjusted earnings per share of $1.63 missed analysts’ expectation of $1.84. Total revenue rose to $51.7m but remained below the consensus of about $59.1m; Captisol and contract revenues also declined. The company emphasizes a strategic shift to a capital‑efficient licensing aggregator, holds roughly $780m in cash and expects the planned acquisition of XOMA to drive meaningful EPS effects and higher license revenues in 2026. Ligand raised its full‑year guidance and sees strong long‑term license growth, but acknowledges near‑term market and valuation risks. » Więcej na de.investing.com